HSF2 and chronic myelogenous leukemia, BCR-ABL1 positive: The results directly demonstrated the involvement of HSF2 in colorectal cancer, renal cell carcinoma, hepatocellular carcinoma, endometrial cancer, small cell lung cancer, chronic myeloid leukemia, and viral carcinogenesis (Figures 6, 7).